These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
113 related articles for article (PubMed ID: 27460981)
1. Advances in high-resolution MS and hepatocyte models solve a long-standing metabolism challenge: the loratadine story. Aratyn-Schaus Y; Ramanathan R Bioanalysis; 2016 Aug; 8(16):1645-62. PubMed ID: 27460981 [TBL] [Abstract][Full Text] [Related]
2. Metabolism and excretion of loratadine in male and female mice, rats and monkeys. Ramanathan R; Alvarez N; Su AD; Chowdhury S; Alton K; Stauber K; Patrick J Xenobiotica; 2005 Feb; 35(2):155-89. PubMed ID: 16019945 [TBL] [Abstract][Full Text] [Related]
3. A long-standing mystery solved: the formation of 3-hydroxydesloratadine is catalyzed by CYP2C8 but prior glucuronidation of desloratadine by UDP-glucuronosyltransferase 2B10 is an obligatory requirement. Kazmi F; Barbara JE; Yerino P; Parkinson A Drug Metab Dispos; 2015 Apr; 43(4):523-33. PubMed ID: 25595597 [TBL] [Abstract][Full Text] [Related]
4. Identification of human UDP-glucuronosyltransferase enzyme(s) responsible for the glucuronidation of 3-hydroxydesloratadine. Ghosal A; Yuan Y; Hapangama N; Su AD; Alvarez N; Chowdhury SK; Alton KB; Patrick JE; Zbaida S Biopharm Drug Dispos; 2004 Sep; 25(6):243-52. PubMed ID: 15334623 [TBL] [Abstract][Full Text] [Related]
5. Metabolism of desloratadine by chimeric TK-NOG mice transplanted with human hepatocytes. Uehara S; Yoneda N; Higuchi Y; Yamazaki H; Suemizu H Xenobiotica; 2020 Jun; 50(6):733-740. PubMed ID: 31690163 [TBL] [Abstract][Full Text] [Related]
6. Hepatocyte spheroids as a viable Chacko SA; Ly VT; Christopher LJ; Gan J Xenobiotica; 2020 Jun; 50(6):621-629. PubMed ID: 31566996 [TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and Tissue Distribution of Loratadine, Desloratadine and Their Active Metabolites in Rat based on a Newly Developed LC-MS/MS Analytical Method. Zhang Y; Lu Y; Wang L; Tian Y; Zhang Z Drug Res (Stuttg); 2020 Nov; 70(11):528-540. PubMed ID: 32877950 [TBL] [Abstract][Full Text] [Related]
8. Disposition of loratadine in healthy volunteers. Ramanathan R; Reyderman L; Kulmatycki K; Su AD; Alvarez N; Chowdhury SK; Alton KB; Wirth MA; Clement RP; Statkevich P; Patrick JE Xenobiotica; 2007 Jul; 37(7):753-69. PubMed ID: 17620221 [TBL] [Abstract][Full Text] [Related]
9. Structural characterization of in vitro rat liver microsomal metabolites of antihistamine desloratadine using LTQ-Orbitrap hybrid mass spectrometer in combination with online hydrogen/deuterium exchange HR-LC/MS. Chen G; Daaro I; Pramanik BN; Piwinski JJ J Mass Spectrom; 2009 Feb; 44(2):203-13. PubMed ID: 18853472 [TBL] [Abstract][Full Text] [Related]
10. Metabolism of loratadine and further characterization of its in vitro metabolites. Ghosal A; Gupta S; Ramanathan R; Yuan Y; Lu X; Su AD; Alvarez N; Zbaida S; Chowdhury SK; Alton KB Drug Metab Lett; 2009 Aug; 3(3):162-70. PubMed ID: 19702548 [TBL] [Abstract][Full Text] [Related]
11. Determination of loratadine and its active metabolite in human plasma by high-performance liquid chromatography with mass spectrometry detection. Vlase L; Imre S; Muntean D; Leucuta SE J Pharm Biomed Anal; 2007 Jul; 44(3):652-7. PubMed ID: 16962733 [TBL] [Abstract][Full Text] [Related]
12. Characterization of Ganstigmine metabolites in hepatocytes by low- and high-resolution mass spectrometry coupled with liquid chromatography. Pelizzi N; Puccini P; Riccardi B; Acerbi D; Catinella S Rapid Commun Mass Spectrom; 2003; 17(15):1691-8. PubMed ID: 12872272 [TBL] [Abstract][Full Text] [Related]
13. Further Characterization of the Metabolism of Desloratadine and Its Cytochrome P450 and UDP-glucuronosyltransferase Inhibition Potential: Identification of Desloratadine as a Relatively Selective UGT2B10 Inhibitor. Kazmi F; Yerino P; Barbara JE; Parkinson A Drug Metab Dispos; 2015 Sep; 43(9):1294-302. PubMed ID: 26135009 [TBL] [Abstract][Full Text] [Related]
14. General unknown screening procedure for the characterization of human drug metabolites: Application to loratadine phase I metabolism. Picard N; Dridi D; Sauvage FL; Boughattas NA; Marquet P J Sep Sci; 2009 Jul; 32(13):2209-17. PubMed ID: 19569100 [TBL] [Abstract][Full Text] [Related]
15. Application of a Micropatterned Cocultured Hepatocyte System To Predict Preclinical and Human-Specific Drug Metabolism. Ballard TE; Wang S; Cox LM; Moen MA; Krzyzewski S; Ukairo O; Obach RS Drug Metab Dispos; 2016 Feb; 44(2):172-9. PubMed ID: 26608083 [TBL] [Abstract][Full Text] [Related]
16. Disposition of desloratadine in healthy volunteers. Ramanathan R; Reyderman L; Su AD; Alvarez N; Chowdhury SK; Alton KB; Wirth MA; Clement RP; Statkevich P; Patrick JE Xenobiotica; 2007 Jul; 37(7):770-87. PubMed ID: 17620222 [TBL] [Abstract][Full Text] [Related]
17. Development and validation of high-throughput liquid chromatography-tandem mass spectrometric method for simultaneous quantification of loratadine and desloratadine in human plasma. Srinubabu G; Patel RS; Shedbalkar VP; Rao AA; Rao MN; Bandaru VV J Chromatogr B Analyt Technol Biomed Life Sci; 2007 Dec; 860(2):202-8. PubMed ID: 18006392 [TBL] [Abstract][Full Text] [Related]
18. Assessment of a micropatterned hepatocyte coculture system to generate major human excretory and circulating drug metabolites. Wang WW; Khetani SR; Krzyzewski S; Duignan DB; Obach RS Drug Metab Dispos; 2010 Oct; 38(10):1900-5. PubMed ID: 20595376 [TBL] [Abstract][Full Text] [Related]
19. Prevalence of Desloratadine Slow-metabolizer Phenotype and Food-dependent Pharmacokinetics of Desloratadine in Healthy Chinese Volunteers. Wang T; Zhang K; Li T; He L; Xie H; Jiang X; Wang L Clin Drug Investig; 2015 Dec; 35(12):807-13. PubMed ID: 26446005 [TBL] [Abstract][Full Text] [Related]
20. Assessing satisfaction with desloratadine and fexofenadine in allergy patients who report dissatisfaction with loratadine. Glass DJ; Harper AS BMC Fam Pract; 2003 Aug; 4():10. PubMed ID: 12917016 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]